As vaccines complete the different phases of development (pre-clinical, phase I, phase II, phase III, regulatory review, and license), results will be published in the scientific literature and announced to the public through the media and press releases. We our currently working as part of a larger group to interview experts and give better guidance on the timelines and probabilities of success for a vaccine against COVID-19. In the meantime, it is important not to read too much into early stage results—this is why.
CGD Policy Blogs
Building Back Better: Creating Resilience in Critical Supply Chains While Supporting Global Development
Policy forged at pace and during extreme circumstances will often leave something wanting. We want more resilient supply chains, but we shouldn’t sacrifice the benefits that existing supply chains have created, nor should we needlessly penalize developing countries in the race for resilience.
This blog outlines some of the challenges in the global supply of medicines and introduces a methodology that will enable countries to spot early challenges in supply.
Around the world COVID-19 and the policy responses to it are causing unprecedented disruptions of life and wellbeing. As scientists and governments around the world race to develop a vaccine at scale, we take a look at what a portfolio approach entails and why it is so important.
President Trump recently delegated authority—under the Defense Production Act—to the US International Development Finance Corporation (DFC) to support domestic production of medical equipment.
Maintaining Essential Services in the Time of COVID-19: Vaccination Delivery in Low- and Middle-Income Countries
As we observe World Immunisation Week, the implications of COVID-19’s spread for routine childhood vaccination delivery are already becoming clear.
DFIs are well positioned to address five pressure points in the COVID-19 response that need financing. Let’s unpack these one by one.
When Fewer Is Better: Pharmaceutical Wholesaling and Distribution in Low- and Middle-Income Countries
In many LMICs, the market of pharmaceutical wholesalers and distributors is extremely fragmented, with too many intermediaries and small, inefficient firms. China and Tanzania provide two examples of reforms.
Poor quality medicines pose significant risks to global health. This blog responds to a recent report from the National Academies that out clear recommendations to global, national and agency level stakeholders which can help strengthen food and medical products regulatory systems in low- and middle-income countries.
Value Chains as Vehicles for Development: Gloomy Global Trends, Optimism in Africa, and Some Ideas for Action
The World Development Report 2020 released on Wednesday highlights the economic benefits from GVCs and reminds us that protectionism and policy uncertainty around the world is now putting many of these benefits at significant risk.